Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 3:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,190 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: CNS Brain Cancer Clear all
Recruiting Phase 1 Interventional

GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults

NCT07087002
View directory record Official record
Conditions
Medulloblastoma, Central Nervous System Embryonal Tumor, Refractory Medulloblastoma, Recurrent Medulloblastoma, Pediatric Brain Tumor, Embryonal Tumor With Multilayered Rosettes (ETMR), Pineoblastoma, Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS, CNS Neuroblastoma, FOXR2-activated
Interventions
GPC2-CAR T cells, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 30 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jul 23, 2026, 3:42 PM EDT
Terminated Phase 2 Interventional

Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma

NCT00005812
View directory record Official record
Conditions
Brain Tumors, Central Nervous System Tumors, Leptomeningeal Metastases
Interventions
temozolomide
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Jul 23, 2026, 3:42 PM EDT
Recruiting Not applicable Interventional

Intravital Microscopy in Human Solid Tumors

NCT03823144
View directory record Official record
Conditions
Solid Tumor, Adult, Clinical Stage IV Gastric Cancer AJCC v8, Malignant Solid Neoplasm, Metastatic Colorectal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Primary Malignant Brain Neoplasm, Metastatic Sarcoma, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Resectable Colorectal Carcinoma, Resectable Liver and Intrahepatic Bile Duct Carcinoma, Resectable Pancreatic Carcinoma, Resectable Sarcoma, Stage IV Colorectal Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Malignant Brain Neoplasm, Metastatic Breast Carcinoma, Metastatic Liver Carcinoma, Metastatic Pancreatic Carcinoma, Resectable Brain Neoplasm, Resectable Breast Carcinoma, Resectable Gastric Carcinoma, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Diagnostic Microscopy, Fluorescein Sodium Injection
Device · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 23, 2026, 3:42 PM EDT
Recruiting Phase 1Phase 2 Interventional

Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms

NCT02638701
View directory record Official record
Conditions
Aneurysm, Stroke, Vasculitis, Tumor Necrosis Factor-alpha
Interventions
Infliximab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 23, 2026, 3:42 PM EDT
Enrolling by invitation Not applicable Interventional

Goals of Care Conversations Study

NCT05001009
View directory record Official record
Conditions
Seriously Ill Patients, Cancer, Heart Failure, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, End-stage Renal Disease, End-stage Liver Disease, Dementia
Interventions
Clinician Implementation Strategy Stage 1: low intensity clinician training, Clinician Implementation Strategy Stage 2: high intensity clinician training, Low patient engagement, High patient engagement
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Palo Alto, California • West Los Angeles, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Jul 23, 2026, 3:42 PM EDT
Not listed Phase 2 Interventional

Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme

NCT00906516
View directory record Official record
Conditions
Brain Tumors
Interventions
Neuradiab in combination with Bevacizumab (Avastin)
Drug
Lead sponsor
Bradmer Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 20, 2009 · Synced Jul 23, 2026, 3:42 PM EDT
Completed No phase listed Observational

Radiation-Induced Cytokine Cascades and Their Correlation With Central Nervous System Injury

NCT00178295
View directory record Official record
Conditions
Brain Neoplasm
Interventions
Radiation Therapy
Radiation
Lead sponsor
University of Rochester
Other
Eligibility
Not listed
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2015 · Synced Jul 23, 2026, 3:42 PM EDT
Completed Phase 2 Interventional

CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme

NCT00016328
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
temsirolimus, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Jul 23, 2026, 3:42 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme

NCT00890032
View directory record Official record
Conditions
Recurrent Central Nervous System Neoplasm
Interventions
BTSC mRNA-loaded DCs
Biological
Lead sponsor
John Sampson
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2016 · Synced Jul 23, 2026, 3:42 PM EDT
Terminated No phase listed Observational

Methionine and PBR28-PET (Peripheral Benzodiazepine Receptors) in Brain Metastases Following Radiosurgery

NCT02433171
View directory record Official record
Conditions
Brain Metastasis
Interventions
Standard of Care FDG-PET Imaging
Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 27, 2019 · Synced Jul 23, 2026, 3:42 PM EDT
Terminated Phase 1 Interventional

RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors

NCT04525014
View directory record Official record
Conditions
Brain Tumor, Recurrent, Brain Tumor, Pediatric, Central Nervous System Neoplasms, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
RRx-001, Temozolomide, Irinotecan
Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
1 Year to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Jul 23, 2026, 3:42 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

NCT03207867
View directory record Official record
Conditions
NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer, Urothelial Cancer, Head and Neck Cancer, DLBCL, Diffused Large B Cell Lymphoma, MSS, Microsatellite Stable Colon Cancer, TNBC, Triple Negative Breast Cancer, Melanoma, mCRPC, Metastatic Castration Resistant Prostate Cancer
Interventions
NIR178, PDR001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Santa Monica, California • Tampa, Florida • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jul 23, 2026, 3:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their Caregivers

NCT03538587
View directory record Official record
Conditions
Glioblastomas, Sarcoma, Astrocytoma, Brain Cancer, Leukemia
Interventions
Enhanced Mindfulness Intervention, Psychoeducation
Behavioral
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years to 24 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Jul 23, 2026, 3:42 PM EDT
Completed Early Phase 1 Interventional

Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study

NCT01737671
View directory record Official record
Conditions
Brain Tumor, Malignant Neoplasm of Fourth Ventricle of Brain
Interventions
Ommaya Reservoir, Methotrexate, Leucovorin
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 22 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Jul 23, 2026, 3:42 PM EDT
Withdrawn Phase 3 Interventional

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

NCT04361552
View directory record Official record
Conditions
Cerebrovascular Accident, Chronic Obstructive Pulmonary Disease, Chronic Renal Failure, Coronary Artery Disease, Diabetes Mellitus, Malignant Neoplasm, SARS Coronavirus 2 Infection
Interventions
Best Practice, Tocilizumab
Other · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Jul 23, 2026, 3:42 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Jul 23, 2026, 3:42 PM EDT
Completed Phase 1 Interventional

O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors

NCT00003765
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
O6-benzylguanine, carmustine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
51
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Jul 23, 2026, 3:42 PM EDT
Recruiting Early Phase 1 Interventional

A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.

NCT07017816
View directory record Official record
Conditions
CNS Malignancies, Medulloblastoma Recurrent, ATRT Recurrent, Pineoblastoma, Embryonal Neoplasm, Ependymoma Recurrent, High Grade Gliomas
Interventions
SGT-53, hypofractionated radiotherapy with immunotherapy, Nivolumab
Drug · Radiation
Lead sponsor
Children's National Research Institute
Other
Eligibility
3 Years to 21 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jul 23, 2026, 3:42 PM EDT
Not listed Not applicable Interventional

The Vitality Project for Fatigued Female Cancer Survivors

NCT03259438
View directory record Official record
Conditions
Fatigue, Cancer Survivorship
Interventions
Qigong, Healthy Living (CHIP + Pre-Train)
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Jul 23, 2026, 3:42 PM EDT
Completed No phase listed Observational

Chemotherapeutic Agents in Brain/Breast

NCT00795678
View directory record Official record
Conditions
Breast Cancer, Metastatic Cancer
Interventions
capecitabine, cyclophosphamide, doxorubicin hydrochloride, gemcitabine hydrochloride, lapatinib ditosylate, paclitaxel, vinorelbine ditartrate, Trastuzumab
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Jul 23, 2026, 3:42 PM EDT
Not listed Phase 2 Interventional

Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma

NCT00004204
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
10
States / cities
Stanford, California • Miami Beach, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Jul 23, 2026, 3:42 PM EDT
Completed Not applicable Interventional

Comparing Smartphone Technology and a Memory Strategy on Improving Prospective Memory in Alzheimer's Disease

NCT03384043
View directory record Official record
Conditions
Alzheimer Disease, Cognitive Impairment, Mild, Dementia, Mild
Interventions
Smartphone Personal Assistant, Implementation Intention
Behavioral
Lead sponsor
Baylor University
Other
Eligibility
Not listed
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Jul 23, 2026, 3:42 PM EDT
Completed Phase 1 Interventional

Phase I, Open Label, Single Center Safety Study of [F-18]FLT

NCT00553748
View directory record Official record
Conditions
Brain Cancer
Interventions
F-18 FLT
Drug
Lead sponsor
Siemens Molecular Imaging
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2008 · Synced Jul 23, 2026, 3:42 PM EDT
Recruiting Phase 1 Interventional

GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma

NCT06815432
View directory record Official record
Conditions
Glioblastoma Multiforme of Brain
Interventions
15.GPC3-CAR T cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2044
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jul 23, 2026, 3:42 PM EDT